Uptake of BRCA 1 / 2 and oncotype DX testing by medical and surgical oncologists

ConclusionsNearly one in five providers never or rarely ever orderedBRCA 1/2 testing for their breast cancer patients, and nearly 15% never or rarely ever ordered Oncotype DX. Less frequent ordering ofBRCA 1/2 is associated with less frequent use of Oncotype DX testing, and vice versa. Those who do not orderBRCA 1/2 testing report less positive attitudes toward genetic innovation. Further education of this subset of providers regarding the benefits of precision medicine may enable more rapid diffusion of genetic technology.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research